

Wei Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5873454/publications.pdf>

Version: 2024-02-01

34
papers

2,724
citations

304743

22
h-index

361022

35
g-index

38
all docs

38
docs citations

38
times ranked

4499
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular imaging of tumor-associated macrophages in cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210761.	3.2	13
2	Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance. <i>BioMed Research International</i> , 2022, 2022, 1-12.	1.9	5
3	Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer. <i>Cell Death and Disease</i> , 2022, 13, 249.	6.3	20
4	Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 813-826.	3.6	18
5	Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance. <i>Cell Death and Disease</i> , 2021, 12, 152.	6.3	26
6	Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth. <i>EBioMedicine</i> , 2020, 51, 102570.	6.1	58
7	Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. <i>Cell Death and Disease</i> , 2020, 11, 381.	6.3	38
8	<p>>Sinomenine Inhibits Non-Small Cell Lung Cancer via Downregulation of Hexokinases II-Mediated Aerobic Glycolysis</p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3209-3221.	2.0	17
9	Promotion of ubiquitination-dependent survivin destruction contributes to xanthohumol-mediated tumor suppression and overcomes radioresistance in human oral squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 88.	8.6	24
10	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq0 0 0 rBT /Overlock 10 Tf 50 8, 1132-1143.	10.7	169
11	<p>>Inhibition of ERKs/Akt-Mediated c-Fos Expression Is Required for Piperlongumine-Induced Cyclin D1 Downregulation and Tumor Suppression in Colorectal Cancer Cells</p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5591-5603.	2.0	9
12	Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3 β /FBW7-mediated Mcl-1 destabilization. <i>Cell Death and Disease</i> , 2020, 11, 143.	6.3	39
13	Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 62.	8.6	32
14	<p>>Inhibition of EGFR Signaling and Activation of Mitochondrial Apoptosis Contribute to Tanshinone IIA-Mediated Tumor Suppression in Non-Small Cell Lung Cancer Cells</p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2757-2769.	2.0	20
15	Xanthohumol targets the ERK1/2–Fra1 signaling axis to reduce cyclin D1 expression and inhibit non–small cell lung cancer. <i>Oncology Reports</i> , 2020, 44, 1365-1374.	2.6	8
16	Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin. <i>Oncogene</i> , 2019, 38, 7457-7472.	5.9	58
17	Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2233-2245.	4.1	31
18	Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells. <i>International Journal of Biological Sciences</i> , 2019, 15, 826-837.	6.4	46

#	ARTICLE	IF	CITATIONS
19	Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. <i>International Journal of Biological Sciences</i> , 2019, 15, 2497-2508.	6.4	58
20	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies. <i>Cancer Research</i> , 2018, 78, 2457-2462.	0.9	92
21	Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway. <i>Cancer Medicine</i> , 2018, 7, 208-218.	2.8	42
22	Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 6213-6227.	3.6	29
23	Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity. <i>International Journal of Biological Sciences</i> , 2018, 14, 1521-1534.	6.4	23
24	Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway. <i>Cellular Signalling</i> , 2018, 50, 131-141.	3.6	40
25	Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway. <i>Oncotarget</i> , 2018, 9, 152-166.	1.8	25
26	Neolbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. <i>Molecular Carcinogenesis</i> , 2017, 56, 1414-1426.	2.7	35
27	Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma. <i>EBioMedicine</i> , 2017, 26, 100-111.	6.1	34
28	Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis. <i>BMC Cancer</i> , 2017, 17, 449.	2.6	42
29	Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis. <i>Oncotarget</i> , 2017, 8, 32586-32599.	1.8	58
30	Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. <i>Experimental Cell Research</i> , 2016, 349, 320-327.	2.6	76
31	EZH2-mediated <i>Puma</i> gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. <i>Oncotarget</i> , 2016, 7, 56338-56354.	1.8	41
32	HIF-1 α pathway: role, regulation and intervention for cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 378-389.	12.0	1,377
33	3,6,2,4,5-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer. <i>Journal of Biological Chemistry</i> , 2014, 289, 28192-28201.	3.4	17
34	TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer. <i>Cancer Research</i> , 2013, 73, 6938-6950.	0.9	89